A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Clinical trial NCT05989542 · RECRUITING

Trial details

NCT number: NCT05989542
Sponsor: Beijing Pearl Biotechnology Limited Liability Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2023-10-16
Primary completion: 2026-09-30
Enrollment: 136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.